Sign In
Buy PTCT
$68.68
+0.450 (+0.660%)
At Close: Jun 03, 2026
PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program
04:34pm, Monday, 20'th Sep 2021
SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer stu
SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Trans
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
08:00am, Friday, 27'th Aug 2021
SOUTH PLAINFIELD, N.J., Aug. 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Morgan Stanley
PTC Therapeutics' Waylivra Scores Approval In Brazil For Genetic Disorder
07:06am, Tuesday, 24'th Aug 2021
The Brazilian Health Regulatory Agency has approved PTC Therapeutics Inc's (NASDAQ: PTCT) Waylivra (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS). The approval
PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome
04:30pm, Monday, 23'rd Aug 2021
SOUTH PLAINFIELD, N.J., Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância San
SOUTH PLAINFIELD, N.J., Aug. 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency an
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2021 Results - Earnings Call Transcript
11:16pm, Thursday, 29'th Jul 2021
PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2021 Results - Earnings Call Transcript
Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™
05:00pm, Wednesday, 28'th Jul 2021
SOUTH PLAINFIELD, N.J., July 28, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England J
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results
08:00am, Thursday, 15'th Jul 2021
SOUTH PLAINFIELD, N.J., July 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 fina
Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy
08:00am, Wednesday, 23'rd Jun 2021
SOUTH PLAINFIELD, N.J., June 23, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™ (risdiplam) was approved in Japan by the Japanese Ministry of Health, Labo
SOUTH PLAINFIELD, N.J., June 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomati
Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors
08:00am, Wednesday, 09'th Jun 2021
SOUTH PLAINFIELD, N.J., June 9, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Mary L.
PTC Therapeutics' (PTCT) PTC923 Gets Orphan Drug Tag in US & EU
11:17am, Thursday, 27'th May 2021
The FDA and the European Commission bestow Orphan Drug status to PTC Therapeutics' (PTCT) PTC923 for the treatment of hyperphenylalaninemia.
PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia
08:00am, Wednesday, 26'th May 2021
SOUTH PLAINFIELD, N.J., May 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC)
PTC Therapeutics to Participate at Upcoming Virtual Investor Conference
08:00am, Wednesday, 19'th May 2021
SOUTH PLAINFIELD, N.J., May 19, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41
